Physician profile
Prashant Vempati
NPI 1487017935
$657.50
in general payments reported to CMS, 2019-2025
7 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $352 · 2024: $158 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $294.19 | 2023-2025 | Illuccix |
| Monteris Medical Corporation | $159.49 | 2023 | Neuroblate |
| Gt Medical Technologies, INC | $142.78 | 2023-2024 | Gammatile, Gammatile |
| Jazz Pharmaceuticals INC. | $25.77 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $20.49 | 2025 | Imfinzi |
| Novocure INC. | $14.78 | 2025 | Optune Lua (Novottf-200t) |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Vempati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.